Table 2.
Pooled incidence and estimated global burden among 1 month-99 year olds in 2016 for selected clinical entities.
| HSV clinical entity | Pooled incidence (95%CI) (cases per 100,000 person-years) | No. of contributing studies | I2 | Cochrane’s Q test | Estimated no. of global cases among 1 month-99 year olds in 2016 in millions (95%CI) |
|---|---|---|---|---|---|
| Any keratitis | 24.0 (14.0–41.0) | 228, 36 | 97.7% | p < .001 | 1.7 (1.0–3.0) |
| Any new keratitis | 9.2 (6.4–13.2) | 328, 32, 36 | 93.6% | p < .001 | 0.7 (0.5–1.0) |
| Any recurrent keratitis | 14.8 (9.8–22.4) | 228, 36 | 93.8% | p < .001 | 1.1 (0.7–1.6) |
| All epithelial keratitis | 16.1 (11.6–22.3) | 328, 30, 36 | 92.6% | p < .001 | 1.2 (0.8–1.6) |
| New epithelial keratitis | 6.4 (5.2–7.9) | 228, 32 | 65.3% | p = .090 | 0.5 (0.4–0.6) |
| All stromal keratitis | 4.9 (1.4–17.0) | 228, 36 | 97.5% | p < .001 | 0.4 (0.1–1.2) |
| New stromal keratitis | 1.1 (0.4–3.5) | 228, 32 | 88.1% | p = .004 | 0.1 (0.0–0.3) |
| New uveitis | 0.2 (0.0–1.1) | 228, 32 | 80.6% | p = .023 | 0.0 (0.0–0.1) |
| New retinitis | 0.01 (0.01–0.02) | 315, 16, 32 | 0.0% | p = .949 | 0.00 (0.00–0.00) |
| New blepharo-conjunctivitis | 3.2 (1.8–5.5) | 228, 32 | 91.1% | p = .001 | 0.2 (0.1–0.4) |
Values do not necessarily sum across rows due to different studies contributing estimates, and potential contribution of endothelial keratitis to estimates for any keratitis. I2 is the percentage of the variation between the estimates explained by between-study variation (i.e., it is a measure of the heterogeneity between studies). Cochrane’s Q test assesses whether the estimates are significantly different between studies. All values shown to 1 d.p., except for pooled incidence estimates and estimated number of global cases for new retinitis which are shown to 2 d.p.